NEW YORK STOCK EXCHANGE, INC. · MRK

+0.00% · +$0.0000 · Vol Not reported

Pre-market · updated 04:01:03 ET

Merck & Co Inc

Pharmaceuticals

$151.64

Card

Relationship Map

Veridion Score

BETAHIGH CONF · 6 of 6 factors measured

Wed Sep 2 · last completed session · Pre-market · regular session opens 9:30 ET · MRK

Methodology

MRK

Merck & Co Inc

Wed Sep 2 · last completed session · Pre-market · regular session opens 9:30 ET

73/100

Upper range

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

73/ 100

Veridion Score

Upper range · HIGH confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6 of 6 factors measured · Wed Sep 2 · last completed session · Pre-market · regular session opens 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is MRK moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move MRK next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Form 4 / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Sep 2
Score
Score moved +14
59/Middle range -> 73/Upper range
Veridion score historySource
Aug 13
Form 4Checking access
Zachary Jennifer Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 13
Form 4Checking access
Guindo Chirfi Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 12
Form 4Checking access
DeLuca Richard R. Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 10
Form 4Checking access
DeLuca Richard R. Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 7
Form 4Checking access
Williams David Michael Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 7
Form 4Checking access
Guindo Chirfi Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 7
Form 4Checking access
Maraldo David R. Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Jul 8
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 16
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Merck & Co Inc

PHARMACEUTICAL PREPARATIONS

Listed since

1949

Employees

75K

Country

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$151.64

Last session

Day high

$151.64

Last session

Day low

$151.64

Last session

Previous close

$151.64

52W high

$156.45

-3.07% from high

52W low

$77.60

94% of range

Market cap

$374.1B

P/E

83.32×

EPS

$1.82

Beta

-0.25

Shares out

2.5B

Avg volume

10.3M

VWAP

$151.64

Last session

Price history computed in-house

+1.40%

+18.47%

+25.54%

+80.14%

YTD

+44.06%

SMA 50 $133.46 · above

SMA 200 $117.82 · above

52W position 94%

MRK overview

Veridion Score

Registered · 2026-09-02

6 of 6 factors measured

Latest receipt rows

Ro Khanna · Purchase

13F holders

Fisher Asset Management, LLC

Receipt-backed holder profiles

Fisher Asset Management, LLC · $4.9B

SEC industry peers

MRK peers

ABBVAbbVie Inc.SEC SIC 2834

ABBV Form 10-K · SEC SIC 2834 · Feb 20, 2026 ↗

BMYBRISTOL MYERS SQUIBB COSEC SIC 2834

BMY Form 10-K · SEC SIC 2834 · Feb 11, 2026 ↗

JNJJOHNSON & JOHNSONSEC SIC 2834

JNJ Form 10-K · SEC SIC 2834 · Feb 11, 2026 ↗

LLYELI LILLY & CoSEC SIC 2834

LLY Form 10-K · SEC SIC 2834 · Feb 12, 2026 ↗

PFEPFIZER INCSEC SIC 2834

PFE Form 10-K · SEC SIC 2834 · Feb 26, 2026 ↗

Relationship mapTrace receipt-backed holders and filings around MRK.Congress disclosuresOpen receipt and filing context for MRK.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

MRK insider activity

Merck & Co Inc

Score

73 · Upper range

Pressure

Net selling

Filings

Buys / sells

0 / 17

Net value

-$30.0M

Insiders

Named filers

Guindo Chirfi

EVP, Access, Policy & Comms

Leadership

Zachary Jennifer

EVP, General Counsel

Officer

DeLuca Richard R.

EVP&Pres, Merck Animal Heallth

Leadership

Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$30.0M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Scroll across filed transactions. Filing date stays visible.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-08-13	2026-08-13	Guindo Chirfi	EVP, Access, Policy & Comms	sell	$135.00	10,000	36,613	$1.4M	SEC Form 4
2026-08-13	2026-08-12	Zachary Jennifer	EVP, General Counsel	sell	$133.46	80,315	45,509	$10.7M	SEC Form 4
2026-08-12	2026-08-12	DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	sell	$131.61	11,099	110,767	$1.5M	SEC Form 4